155 results on '"Kappos, A."'
Search Results
2. Corneal Densitometry After Uneventful Descemet Membrane Endothelial Keratoplasty—5-Year Outcomes
3. Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis
4. Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses
5. Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
6. Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
7. Monitoring of radiologic disease activity by serum neurofilaments in MS
8. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
9. Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS
10. Growth differentiation factor 15 is increased in stable MS
11. Hepatitis E virus infections in patients with MS on oral disease-modifying treatment
12. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice
13. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
14. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
15. What Happened after the Poly Implant Prothèse Recall? A Prospective Cohort Study of 808 Implants into the Predictive Value of Implant Rupture on Postexchange Complications
16. Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge
17. α4-integrin receptor desaturation and disease activity return after natalizumab cessation
18. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA
19. Supplement to: Ocrelizumab versus placebo in primary progressive multiple sclerosis.
20. Spinal cord volume loss: A marker of disease progression in multiple sclerosis
21. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
22. The Importance of an Academic Approach to Patient-Oriented Aesthetic Outcome Research: Reply to Comment on “Validating Facial Aesthetic Surgery Results with the FACE-Q”
23. Extending the limits of the anterior tibial artery as the recipient vessel for around the knee and proximal lower extremity defect reconstruction using the free anterolateral thigh and gracilis flap
24. Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study
25. PO129 Neda analysis by epoch in the opera studies of ocrelizumab
26. PO128 Infusion-related reactions with ocrelizumab in rms and ppms
27. PO114 Neda achievement by time interval with daclizumab
28. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
29. Extramedullary plasmacytoma in the airway of an HIV‐positive child
30. Survey of diagnostic and treatment practices for multiple sclerosis in Europe
31. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
32. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
33. Letter Re: Retraction: Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women; Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women: Reply From The Authors
34. Supplement to: Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis.
35. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
36. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
37. Multiple Sclerosis and Antibodies against KIR4.1
38. The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis
39. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
40. Nonconventional MRI and microstructural cerebral changes in multiple sclerosis
41. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b
42. Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
43. Tissue Distribution Dynamics of Human NK Cells Inferred from Peripheral Blood Depletion Kinetics after Sphingosine-1-Phosphate Receptor Blockade
44. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
45. EVIDENCE-BASED GUIDELINES: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients
46. Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis
47. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes
48. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis
49. Comparison between balanced steady-state free precession and standard spoiled gradient echo magnetization transfer ratio imaging in multiple sclerosis: methodical and clinical considerations
50. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.